C4 Therapeutics, Inc.

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutic candidates that degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3 proteins for the treatment of multiple myeloma, which has completed Phase 1 trials. The company is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of the epidermal growth factor receptor with an L858R mutation, aimed at non-small cell lung cancer. Additionally, C4 Therapeutics is working on new degraders targeting inflammation, neuroinflammation, and neurodegeneration. The company leverages strategic collaborations with partners such as F. Hoffmann-La Roche Ltd, Betta Pharmaceuticals Co. Ltd., and Merck KGAA to advance its pipeline.

C4 Therapeutics, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol CCCC. The company's shares are traded in United States Dollars (USD), which is the official currency of the United States. As a US-based company listed on a major US exchange, its financial reporting and stock price are denominated in USD, making it accessible to investors trading on US markets.

C4 Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biopharmaceutical company, it focuses on developing targeted protein degradation therapies for diseases such as cancer and neurodegenerative conditions. The biotechnology industry involves using biological processes and living organisms to develop innovative treatments, and C4 Therapeutics' approach of degrading disease-causing proteins represents a cutting-edge area within this field.

C4 Therapeutics, Inc. is headquartered in Watertown, Massachusetts, United States. The company primarily serves the global pharmaceutical market through its development of novel therapeutic candidates. While its focus is on developing treatments for diseases like multiple myeloma and non-small cell lung cancer, its strategic collaborations with international partners such as F. Hoffmann-La Roche Ltd (Switzerland), Betta Pharmaceuticals Co. Ltd. (China), and Merck KGAA (Germany) indicate a global reach. The company's research and development efforts are centered in the US, but its partnerships enable potential worldwide commercialization of its therapies.

C4 Therapeutics generates revenue primarily through strategic collaborations and partnerships with pharmaceutical companies. The company has entered into agreements with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Notably, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. These collaborations typically involve upfront payments, milestone payments, and royalties on future product sales. As a clinical-stage company, C4 Therapeutics does not yet have approved products generating commercial revenue; its financial model relies on these partnerships to fund its research and development activities until its drug candidates reach the market.